XNAS · Healthcare · Biotechnology
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.66 | -1.84 | -178.79% | $25.6M | ❌ Miss | -0.91% | -8.86% | — |
| 2026-03-03 | Q4 2025 | 0.92 | 1.58 | +71.74% | $108.2M | ✅ Beat | +4.30% | +17.38% | +9.18% |
| 2025-11-04 |
| Q3 2025 |
| -1.17 |
| 0.52 |
| +144.44% |
| $76.3M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | -1.55 | -1.34 | +13.55% | $22.3M | ✅ Beat | +2.04% | -8.07% | -2.84% |
| 2025-05-05 | Q1 2025 | -1.46 | -1.28 | +12.33% | $27.8M | ✅ Beat | — | — | — |
| 2025-02-27 | Q4 2024 | -1.74 | -0.72 | +58.62% | $43.1M | ✅ Beat | — | — | — |
| 2024-11-05 | Q3 2024 | -1.65 | -1.14 | +30.91% | $30.0M | ✅ Beat | — | — | — |
| 2024-08-05 | Q2 2024 | -0.89 | -1.71 | -92.13% | $11.0M | ❌ Miss | — | — | — |
Showing last 8 quarters.